PSA response


Also found in: Dictionary, Thesaurus, Encyclopedia.

PSA response

A decrease in the level of prostate-specific antigen (PSA) of at least 50% in a patient receiving treatment for prostate cancer.
See also: response
References in periodicals archive ?
An NLR of less than five has been shown to be predictive of PSA response to abiraterone.
Prostate-specific antigen response is commonly used in CTs as an efficacy measure for mCRPC response, but the clinical significance of the PSA response is unclear [24].
A post-hoc analysis was conducted in Canadian patients after the database was locked to evaluate the impact of the prior use of abiraterone on cabazitaxel's efficacy assessed based on PSA response, QoL, and safety.
PSA response rates were also statistically significantly higher with docetaxel compared to mitoxantrone.
3: TAX327 data on [greater than or equal to]3-year survival,[sup.7] PSA response, pain reduction and improvement in quality of life.[sup.5] PSA: prostate-specific antigen.
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
These factors include the Gleason score,[sup.22] PSA response to ADT[sup.23] and age.[sup.24] PSA doubling time is probably the most robust factor for predicting overall survival,[sup.24] cause-specific survival[sup.23,25] and chance of distant metastases.[sup.22] Interestingly, the use of PSAdt as a trigger for initiating earlier use of ADT predates any evidence that this alters measurable outcomes in a positive way.
Several prognostic factors in hormone-refractory prostate cancer (HRPC) have been reported, including initial PSA, tumour Gleason grade and stage, as well as baseline hemoglobin, performance status and PSA doubling time (PSADT).[sup.7,8] PSA response (defined as a 50% decline in baseline PSA) has also been proposed as a predictor of survival following chemotherapy for mHRPC.[sup.9] However, the magnitude of this benefit has been variable between studies and there is a need for better predictors of outcome from chemotherapy in mHRPC.[sup.10]-[sup.12]
Editor's Note: The researchers concluded that "treatment with metformin is safe in non-diabetic patients, and it yields objective PSA responses and may induce disease stabilization.
The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.Most previous reports comparing treatment outcomes among different treatment options have looked only at PSA responses to treatment, rather than at the more important long-term survival outcomes, according to the researchers.
The publication reports that in patients evaluable for prostate-specific antigen (PSA) there were seven PSA responses (reductions of greater than 50%), seven disease stabilizations and one disease progression on this regimen of antisense therapy targeting the R2 component of ribonucleotide reductase combined with docetaxel and prednisone.
In this study, we monitored PSA responses in urine and serum, as well as hK2 response in urine, obtained from female-to-male transsexuals undergoing long-term androgenizing treatment with testosterone.